One of the most closely watched healthcare merger disputes is still the Justice Department’s challenge to UnitedHealth Group’s proposed acquisition of Amedisys — and, just as importantly, the government’s willingness to resolve that challenge through a divestiture package rather than insisting on an all-or-nothing court fight.

The proposed settlement, reached with the U.S. Department of Justice and a coalition of state attorneys general from Maryland, Illinois, New Jersey, and New York, would require substantial asset sales to address competitive concerns tied to home health and hospice markets. The matter is pending in federal district court in Washington, D.C., making it a key case for deal lawyers, antitrust litigators, and healthcare executives trying to gauge how regulators are approaching consolidation in 2025.

That is what makes this development so significant. In recent years, antitrust enforcement rhetoric has often suggested deep skepticism toward negotiated fixes in major mergers, particularly structural remedies that rely on divestitures. This settlement signals that, at least in some transactions, the government still sees a path to preserving competition without fully blocking the deal. For companies considering acquisitions in concentrated healthcare markets, that distinction matters. It suggests that remedy negotiations remain viable — but only where the divestiture package is broad enough to satisfy concerns about local market overlap and continuity of care.

For legal professionals, the case offers several practical takeaways. Antitrust litigators should be watching how the court evaluates the adequacy of the proposed remedy and whether any objections emerge around the divested assets, buyer suitability, or post-transaction market dynamics. In-house counsel and deal teams should see this as another reminder that healthcare transactions can trigger scrutiny not only at a national level, but also across specific regional service lines where regulators perceive patient-choice risks. Compliance teams, meanwhile, should pay close attention to any obligations tied to transition services, information sharing, and operational separation during the divestiture process.

The matter also underscores a broader enforcement reality: healthcare remains a priority sector, and regulators are still highly focused on provider roll-ups, home health, hospice, and adjacent care-delivery markets. Even when a settlement is on the table, the cost, scope, and complexity of required divestitures can materially reshape the economics of a deal.

For practitioners tracking merger enforcement trends, this is one of the more important pending developments of the year. Its ultimate resolution may help define when structural remedies are still enough in modern healthcare antitrust review — and when the government will decide that only a full stop will do.